Clinical Rheumatology

, Volume 37, Issue 4, pp 869–874 | Cite as

Reactive arthritis: update 2018

  • A. García-Kutzbach
  • J. Chacón-Súchite
  • H. García-Ferrer
  • I. Iraheta
Review Article

Abstract

At this time, reactive arthritis (ReA) is considered to be part of the spectrum of the spondyloarthritis, previously known as Reiter’s syndrome, and refers to an infection induced systemic illness, characterized by a sterile synovitis occurring in a genetically predisposed individual, secondary to an infection localized in a distant organ/system, but also accompanied with multiple extra articular manifestations.

Keywords

Gut microbiota HLA-B27 Reactive arthritis Reiter’s syndrome Spondyloarthritis 

Notes

Compliance with ethical standards

Conflicts of interest

Abraham Garcia-Kutzbach: serve as Principal Investigator for clinical studies of Merck, Abbie, Novartis, and Janssen

Helga Garcia: Medical Scientific Liaison for Novartis Pharma Central America and Caribbean

Jose A. Chacon and Isa Iraheta do not report conflict of interest.

References

  1. 1.
    Keynan Y, Rimar D (2008) Reactive arthritis—the appropriate name. Isr Med Assoc J 10(4):256–258PubMedGoogle Scholar
  2. 2.
    Panush R, Wallace D, Dorff R, Engleman E (2007) Retraction of the suggestion to use the term «Reiter’s syndrome» sixty-five years later. Arthritis Rheum 56(2):693–694.  https://doi.org/10.1002/art.22374 CrossRefPubMedGoogle Scholar
  3. 3.
    Stavropoulos P, Soura E, Kanelleas A, Katsambas A, Antoniou C (2015) Reactive arthritis. J Eur Acad Dermatology Venereol 29(3):415–424.  https://doi.org/10.1111/jdv.12741 CrossRefGoogle Scholar
  4. 4.
    Hannu T (2011) Reactive arthritis. Best Pract Res Clin Rheumatol 25(3):347–357.  https://doi.org/10.1016/j.berh.2011.01.018 CrossRefPubMedGoogle Scholar
  5. 5.
    Colmegna I, Cuchacovich R, Espinoza L (2004) HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. Clin Microbiol Rev 17(2):348–369.  https://doi.org/10.1128/CMR.17.2.348 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Gupta R, Misra R (2016) Microbe-triggered arthropathies: reactive arthritis and beyond. Int J Rheum Dis 19(5):437–439.  https://doi.org/10.1111/1756-185X.12920 CrossRefPubMedGoogle Scholar
  7. 7.
    Lopez Férez F, García Novo E (1986) Tratados hipocráticos. (eds) Gredos, Madrid, EspañaGoogle Scholar
  8. 8.
    Allison D (1980) Christopher Columbus: first case of Reiter’S disease in the old world? Lancet 316(8207):1309.  https://doi.org/10.1016/S0140-6736(80)92381-8 CrossRefGoogle Scholar
  9. 9.
    Carter J, Hudson A (2009) Reactive arthritis: clinical aspects and medical management. Rheum Dis Clin N Am 35(1):21–44.  https://doi.org/10.1016/j.rdc.2009.03.010 CrossRefGoogle Scholar
  10. 10.
    Manasson J, Shen N, García H, Ubeda C, Iraheta I, Heguy A, Von Feldt J, Espinoza L, García Kutzbach A, Segal L, Ogdie A, Clemente J, Sher J (2017) Gut microbiota perturbations in reactive arthritis and post-infectious Spondyloarthritis arthritis. Rheum.  https://doi.org/10.1002/art.40359 [Epub ahed of print]
  11. 11.
    Ehrenfeld M (2010) Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 9(5):A325–A329.  https://doi.org/10.1016/j.autrev.2009.11.012 CrossRefPubMedGoogle Scholar
  12. 12.
    Szamocki S, Martyn-hemphill C, Green J (2016) Reactive arthritis: can’t see, can’t pee, can’t climb a tree. Trends Urol Men’s Heal 7(1):17–20.  https://doi.org/10.1002/tre.501 CrossRefGoogle Scholar
  13. 13.
    García-Kutzbach A, Montenegro A, Iraheta I, Bará C, Saénz R (2011) Epidemiology of spondyloarthropathies in Central America. Am J Med Sci 341(4):295–297.  https://doi.org/10.1097/MAJ.0b013e31820f8cf1 CrossRefPubMedGoogle Scholar
  14. 14.
    Brewerton D, Hart F, Nicholls A, Caffrey M, James D, Sturrock R (1973) Ankylosing spondylitis and HlA 27. Lancet 301(7809):904–907.  https://doi.org/10.1016/S0140-6736(73)91360-3 CrossRefGoogle Scholar
  15. 15.
    Schlosstein L, Terasaki P, Bluestone R, Pearson C (1973) High association of an HLA antigen, W27 with ankylosing spondylitis. N Engl J Med 288(14):704–705.  https://doi.org/10.1056/NEJM197304052881403 CrossRefPubMedGoogle Scholar
  16. 16.
    Vazquez-Torres A, Vallance B, Bergman M, Finlay B, Cookson B, Jones-Carson J et al (2004) Toll-like receptor 4 dependence of innate and adaptive immunity to salmonella: importance of the Kupffer cell network. J Immunol 172(10):6202–6208.  https://doi.org/10.4049/jimmunol.172.10.6202 CrossRefPubMedGoogle Scholar
  17. 17.
    Reveille JD (2014) An update on the contribution of the MHC to as susceptibility. Clin Rheumatol 33(6):749–757.  https://doi.org/10.1007/s10067-014-2662-7 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Tsui F, Xi N, Rohekar S, Riarh R, Bilotta R, Tsui H et al (2008) Toll-like receptor 2 variants are associated with acute reactive arthritis. Arthritis Rheum 58(11):3436–3438.  https://doi.org/10.1002/art.23967 CrossRefPubMedGoogle Scholar
  19. 19.
    Rihl M, Klos A, Köhler L, Kuipers J (2006) Reactive arthritis. Best Pract Res Clin Rheumatol 20(6):1119–1137.  https://doi.org/10.1016/j.berh.2006.08.008 CrossRefPubMedGoogle Scholar
  20. 20.
    Denison H, Curtis E, Clynes M, Bromhead C, Dennison E, Grainger R (2016) The incidence of sexually acquired reactive arthritis: a systematic literature review. Clin Rheumatol 35(11):2639–2648.  https://doi.org/10.1007/s10067-016-3364-0 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Asquith M, Rosenbaum J (2016) The interaction between host genetics and the microbiome in the pathogenesis of spondyloarthropathies. Curr Opin Rheumatol 28(4):405–412.  https://doi.org/10.1097/BOR.0000000000000299 CrossRefPubMedGoogle Scholar
  22. 22.
    Reveille JD (2012) Genetics of spondyloarthritis—beyond the MHC. Nat Rev Rheumatol 8(5):296–304.  https://doi.org/10.1038/nrrheum.2012.41 CrossRefPubMedGoogle Scholar
  23. 23.
    Pope J, Krizova A, Garg A, Thiessen-Philbrook H, Ouimet J (2007) Campylobacter reactive arthritis: a systematic review. Semin Arthritis Rheum 37(1):48–55.  https://doi.org/10.1016/j.semarthrit.2006.12.006 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Zeidler H, Hudson A (2016) Coinfection of chlamydiae and other bacteria in reactive arthritis and spondyloarthritis: need for future research. Microorganisms 4(3):30.  https://doi.org/10.3390/microorganisms4030030 CrossRefPubMedCentralGoogle Scholar
  25. 25.
    Carter J, Inman R (2011) Chlamydia-induced reactive arthritis: hidden in plain sight? Best Pract Res Clin Rheumatol 25(3):359–374.  https://doi.org/10.1016/j.berh.2011.05.001 CrossRefPubMedGoogle Scholar
  26. 26.
    Gaston J (2005) Shigella induced reactive arthritis. Ann Rheum Dis 64(4):517–518.  https://doi.org/10.1136/ard.2004.030395 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Cargnelutti E, Di Genaro M (2013) Reactive arthritis: from clinical features to pathogenesis. Int J Clin Med 4(12):20–30.  https://doi.org/10.4236/ijcm.2013.412A2004 CrossRefGoogle Scholar
  28. 28.
    Garcia H, Azan A, Iraheta I, Von Feldt J, Espinoza L, Manasson J, Scher J, García Kutzbach A (2017) Potential risk factors for reactive arthritis and persistence of symptoms at 2 years: a case-control study with longitudinal follow-up. Clin Rheumatol.  https://doi.org/10.1007/s10067-017-3911.3 [Epub ahed of print]
  29. 29.
    Van de Wiele T, Van Praet J, Marzorati M, Drennan M, Elewaut D (2016) How the microbiota shapes rheumatic diseases. Nat Rev Rheumatol 12(7):398–411.  https://doi.org/10.1038/nrrheum.2016.85 CrossRefPubMedGoogle Scholar
  30. 30.
    Caminer A, Haberman R, Scher J (2017) Human microbiome, infections, and rheumatic disease. Clin Rheumatol 36(12):2645–2653.  https://doi.org/10.1007/s10067-017-3875-3 CrossRefPubMedGoogle Scholar
  31. 31.
    Brown J, Hazen S (2015) The gut microbial endocrine organ: bacterially-derived signals driving cardiometabolic diseases. Annu Rev Med 66(1):343–359.  https://doi.org/10.1146/annurev-med-060513-093205 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Eckburg P, Bik E, Bernstein C, Purdom E, Dethlefsen L, Sargent M, Gill S, Nelson K, Relman D (2005) Diversity of the human intestinal microbial flora. Science 308(5728):1635–1638.  https://doi.org/10.1126/science.1110591 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Blaser M, Bork P, Fraser C, Knight R, Wang J (2013) The microbiome explored: recent insights and future challenges. Nat Rev Microbiol 11(3):213–217.  https://doi.org/10.1038/nrmicro2973 CrossRefPubMedGoogle Scholar
  34. 34.
    Catrina A, Deane K, Scher J (2016) Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis. Rheumatology 55(3):391–402.  https://doi.org/10.1093/rheumatology/keu469 PubMedGoogle Scholar
  35. 35.
    Wendling D, Prati C (2017) Spondyloarthritis: an expanding cast of cellular actors. Jt bone Spine:1–3.  https://doi.org/10.1016/j.jbspin.2017.05
  36. 36.
    Ericsson A, Hagan C, Davis D, Franklin C (2014) Segmented filamentous bacteria: commensal microbes with potential effects on research. Comp Med 64(2):90–98PubMedPubMedCentralGoogle Scholar
  37. 37.
    Ji B, Nielsen J (2015) New insight into the gut microbiome through metagenomics. Adv Genomics Genet 5:77–91.  https://doi.org/10.2147/AGG.S57215 Google Scholar
  38. 38.
    Ivanov I, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U et al (2009) Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139(3):485–498.  https://doi.org/10.1016/j.cell.2009.09.033 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Miossec P (2017) Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice. RMD 3(1):e000284.  https://doi.org/10.1136/rmdopen-2016-000284 CrossRefGoogle Scholar
  40. 40.
    Riente L, Sedie A, Filippucci E, Iagnocco A, Meenagh G, Grassi W, Valesini G, Bombardieri S (2007) Ultrasound imaging for the rheumatologist IX. Ultrasound imaging in spondyloarthritis. Clin Exp Rheumatol 25(3):349–353PubMedGoogle Scholar
  41. 41.
    Colmegna I, Espinoza L (2005) Recent advances in reactive arthritis. Curr Rheumatol Rep 7(3):201–207.  https://doi.org/10.1007/s11926-996-0040-4 CrossRefPubMedGoogle Scholar
  42. 42.
    Allen-Vercoe E, Reid G, Viner N, Gloor G, Hota S, Kim P, Lee C, O’Doherty K, Vanner S, Weewe S, Petrof E (2012) A Canadian working group report on fecal microbial therapy: microbial ecosystems therapeutics. Can J Gastroenterol 26(7):457–462.  https://doi.org/10.1155/2012/213828

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  1. 1.AGAR, FM - UFM. Asociación Guatemalteca Anti-enfermedades Reumáticas, Facultad de MedicinaUniversidad Francisco MarroquínGuatemala CityGuatemala

Personalised recommendations